Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Leukemia

Free Subscription 06.05.2024 1 Ann Hematol 1 Biochem Pharmacol 2 Blood 2 Br J Cancer 2 Eur J Haematol 3 Int J Hematol 1 J Clin Oncol 1 Leuk Lymphoma 3 Leuk Res 3 N Engl J Med 1 Oncogene 1 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Hematol

1. LIU Y, Liu Y, Chen P, Chen G, et al
   GLI1 polymorphisms influence remission rate and prognosis of young de novo acute myeloid leukemia patients treated with cytarabine-based chemotherapy.
   Ann Hematol. 2024 Apr 27. doi: 10.1007/s00277-024-05777.
   PubMed         Abstract available
   
   

   
   Biochem Pharmacol

2. CHIOU JT, Chang LS
   ONC212 enhances YM155 cytotoxicity by triggering SLC35F2 expression and NOXA-dependent MCL1 degradation in acute myeloid leukemia cells.
   Biochem Pharmacol. 2024;224:116242.
   PubMed         Abstract available
   
   

   
   Blood

3. ROESSNER PM, Seufert I, Chapaprieta V, Jayabalan R, et al
   T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.
   Blood. 2024 Apr 29:blood.2023021990. doi: 10.1182/blood.2023021990.
   PubMed         Abstract available
   
   
4. KRAKOW EF, Brault M, Summers C, Cunningham TM, et al
   HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
   Blood. 2024 Apr 29:blood.2024024105. doi: 10.1182/blood.2024024105.
   PubMed         Abstract available
   
   

   
   Br J Cancer

5. MEDRANO M, Contreras M, Caballero-Velazquez T, Martinez L, et al
   Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions.
   Br J Cancer. 2024;130:1529-1541.
   PubMed         Abstract available
   
   
6. LITTLE MP, Mai JZ, Fang M, Chernyavskiy P, et al
   Solar ultraviolet radiation exposure, and incidence of childhood acute lymphocytic leukaemia and non-Hodgkin lymphoma in a US population-based dataset.
   Br J Cancer. 2024 Feb 29. doi: 10.1038/s41416-024-02629.
   PubMed         Abstract available
   
   

   
   Eur J Haematol

7. TAGHILOO S, Asgarian-Omran H
   Cross-talk between leukemic and immune cells at the tumor microenvironment in chronic lymphocytic leukemia: An update review.
   Eur J Haematol. 2024 May 2. doi: 10.1111/ejh.14224.
   PubMed         Abstract available
   
   
8. KUTSCH N, Giza A, Robrecht S, Stumpf J, et al
   Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
   Eur J Haematol. 2024 May 1. doi: 10.1111/ejh.14220.
   PubMed         Abstract available
   
   

   
   Int J Hematol

9. KAITO Y, Imai Y
   Evolution of natural killer cell-targeted therapy for acute myeloid leukemia.
   Int J Hematol. 2024 May 1. doi: 10.1007/s12185-024-03778.
   PubMed         Abstract available
   
   
10. KATSUKI K, Tachibana T, Izumi A, Kim K, et al
    Acute mixed-lineage leukemia treated with desensitization therapy prior to HLA-haploidentical transplantation with high donor-specific antibodies.
    Int J Hematol. 2024 Apr 27. doi: 10.1007/s12185-024-03775.
    PubMed         Abstract available
    
    
11. TIEN FM, Hou HA
    CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.
    Int J Hematol. 2024 Apr 26. doi: 10.1007/s12185-024-03773.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

12. SHORT NJ, Daver N, Dinardo CD, Kadia T, et al
    Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
    J Clin Oncol. 2024;42:1499-1508.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

13. HUNTINGTON SF, Cheng WY, Sarpong EM, Leng S, et al
    Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study.
    Leuk Lymphoma. 2024 May 2:1-11. doi: 10.1080/10428194.2024.2331631.
    PubMed         Abstract available
    
    

    
    Leuk Res

14. MOHEBBI A, Shahriyary F, Farrokhi V, Bandar B, et al
    A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.
    Leuk Res. 2024;141:107505.
    PubMed         Abstract available
    
    
15. SUN M, Li S, Liu Z, Ma S, et al
    Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: A real-world single-center retrospective study, with a focus on premature drug discontinuation.
    Leuk Res. 2024;142:107507.
    PubMed         Abstract available
    
    
16. DONG S, Premnath N, Sadeghi N, Kainthla R, et al
    Racial and ethnic disparities in Acute Myeloid Leukemia: 15-year experience at a safety net hospital system.
    Leuk Res. 2024;141:107503.
    PubMed         Abstract available
    
    

    
    N Engl J Med

17. MUNIR T, Hillmen P
    Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. Reply.
    N Engl J Med. 2024;390:1634-1635.
    PubMed        
    
    
18. WANG WD, Gale RP, Liang Y
    Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
    N Engl J Med. 2024;390:1633-1634.
    PubMed        
    
    
19. WINKLER C
    Acute Promyelocytic Leukemia.
    N Engl J Med. 2024;390:e42.
    PubMed        
    
    

    
    Oncogene

20. SAFFERTHAL C, Rohde K, Fulda S
    Correction: Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells.
    Oncogene. 2024 Apr 29. doi: 10.1038/s41388-024-03022.
    PubMed        
    
    

    
    PLoS One

21. EISSENBERG LG, Ritchey JK, Rettig MP, Patel DA, et al
    Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager.
    PLoS One. 2024;19:e0300174.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

22. KATERNDAHL CDS, Rogers ORS, Day RB, Xu Z, et al
    PML::RARA and GATA2 proteins interact via DNA templates to induce aberrant self-renewal in mouse and human hematopoietic cells.
    Proc Natl Acad Sci U S A. 2024;121:e2317690121.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.